HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2007.098434v1 54/3/542    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oglesbee, D. Articles by Matern, D. Search for Related Content PubMed PubMed Citation Articles by Oglesbee, D. Articles by Matern, D. Related Collections Pediatric Clinical Chemistry

Second-Tier Test for Quantification of Alloisoleucine and Branched-Chain Amino Acids in Dried Blood Spots to Improve Newborn Screening for Maple Syrup Urine Disease (MSUD)

Departments of¹ Laboratory Medicine and Pathology,² Medical Genetics, and³ Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, MN;⁴ Applied Biosystems, Monza, Italy;⁵ The Clinic for Special Children, Strasburg, PA.

^aAddress correspondence to this author at Biochemical Genetics Laboratory, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. Fax 507-266-2888; e-mail matern{at}mayo.edu.

Background: Newborn screening for maple syrup urine disease (MSUD) relies on finding increased concentrations of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine by tandem mass spectrometry (MS/MS). D-Alloisoleucine (allo-Ile) is the only pathognomonic marker of MSUD, but it cannot be identified by existing screening methods because it is not differentiated from isobaric amino acids. Furthermore, newborns receiving total parenteral nutrition often have increased concentrations of BCAAs. To improve the specificity of newborn screening for MSUD and to reduce the number of diet-related false-positive results, we developed a LC-MS/MS method for quantifying allo-Ile.

Methods: Allo-Ile and other BCAAs were extracted from a 3/16-inch dried blood spot punch with methanol/H₂O, dried under nitrogen, and reconstituted into mobile phase. Quantitative LC-MS/MS analysis of allo-Ile, its isomers, and isotopically labeled internal standards was achieved within 15 min. To determine a reference interval for BCAAs including allo-Ile, we analyzed 541 dried blood spots. We also measured allo-Ile in blinded samples from 16 MSUD patients and 21 controls and compared results to an HPLC method.

Results: Intra- and interassay imprecision (mean CVs) for allo-Ile, leucine, isoleucine, and valine ranged from 1.8% to 7.4%, and recovery ranged from 91% to 129%. All 16 MSUD patients were correctly identified.

Conclusions: The LC-MS/MS method can reliably measure allo-Ile in dried blood spots for the diagnosis of MSUD. Applied to newborn screening as a second-tier test, it will reduce false-positive results, which produce family anxiety and increase follow-up costs. The assay also appears suitable for use in monitoring treatment of MSUD patients.

The following articles in journals at HighWire Press have cited this article:

				R. Fingerhut, E. Simon, E. M. Maier, J. B. Hennermann, and U. Wendel Maple Syrup Urine Disease: Newborn Screening Fails to Discriminate between Classic and Variant Forms Clin. Chem., October 1, 2008; 54(10): 1739 - 1741. [Full Text] [PDF]